

Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Colin Clark Edgerton		
2. Your Title: MD		
3. The Entity(ies) You are Representing: American College of Rheumatology		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No x
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. None		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature: 

Date: 6 NOV 2017

LAST UPDATE: May 2017


Colin C. Edgerton 28 MAY 2017
Signature / Date

CURRICULUM VITAE

Colin C. Edgerton, MD, FACP, FACR, RhMSUS

PERSONAL INFORMATION

Home address and telephone:



Professional address and telephone:

Articularis Healthcare Group, Inc
d/b/a Low Country Rheumatology (Oct 2016 – Present)
2860 Tricom Street
Charleston, SC 29406
(843) 572-1818 (p), (843) 572-1824(f)

Low Country Rheumatology, PA (May 2013 – Oct 2016)
2860 Tricom Street
Charleston, SC 29406
(843) 572-1818 (p), (843) 572-1824(f)
E-mail address: edgerton2860@gmail.com

EDUCATION/POST GRADUATE TRAINING

1993-1997	Georgetown University Washington, DC Bachelor of Science (Biology)
1997-2001	Georgetown University School of Medicine Washington, DC Doctor of Medicine, <i>Cum Laude</i> , AOA
2001-2002	Internship, Internal Medicine Madigan Army Medical Center Tacoma, WA
2002-2004	Residency, Internal Medicine Madigan Army Medical Center Tacoma, WA
2004-2006	Fellowship, Rheumatology Walter Reed Army Medical Center Washington, DC

MEDICAL LICENSURE

South Carolina #MD 35120
Nebraska #22460

BOARD CERTIFICATION AND CREDENTIALS

American Board of Internal Medicine: Internal Medicine
American Board of Internal Medicine: Rheumatology
Musculoskeletal Ultrasound Certification in Rheumatology

PROFESSIONAL POSITIONS AND APPOINTMENTS

2013-Present	Articularis Healthcare Group, Inc Low Country Rheumatology Charleston, SC
2006-2013	Chief, Rheumatology Service Eisenhower Army Medical Center Fort Gordon, GA
2007-present	Clinical Assistant Professor, Dept. of Medicine Medical College of Georgia Augusta, GA
2009-present	American Medical Association Alternate Delegate for the American College of Rheumatology
2010-present	Assistant Professor of Medicine Uniformed Services University of the Health Sciences Bethesda, MD
2010-present	Musculoskeletal Ultrasound Task Force for the American College of Rheumatology
2011-2013	Governing Council Member for the American Medical Association Young Physician Section
2012-present	Committee on Rheumatologic Care, American College of Rheumatology

TEACHING ACTIVITIES

2011-2013 Musculoskeletal Ultrasound Preceptor, Rheumatology
Fellowship Training Program, Medical College of Georgia
2006-2013 Rheumatology Educational Curriculum Coordinator,
Graduate Medical Education, Eisenhower Medical Center
2004 Stanford Faculty Development Seminar

HOSPITAL/UNIVERSITY COMMITTEE APPOINTMENTS

2011-2012 Chair, Institutional Review Board, Eisenhower Army
Medical Center
2006-2013 Institutional Review Board Member, Eisenhower Army
Medical Center

HONORS AND AWARDS

2001 AOA, Georgetown University School of Medicine
2004 Robert Skelton Award for Top Graduating Resident, Madigan Army
Medical Center
2006 Bailey K. Ashford Laboratory Research Finalist, Walter Reed Army
Medical Center
2006 Mid-Atlantic Rheumatology Fellows' Forum Podium Presentation Winner
2010 Fellow, American College of Physicians

MILITARY HONORS AND AWARDS

Bronze Star Medal: Awarded for Meritorious Service in Combat Operations;
Operation Iraqi Freedom
Combat Medical Badge: Awarded for Provision of Medical Care Under Direct
Enemy Fire; Operation Iraqi Freedom
Meritorious Service Medal
Army Commendation Medal with two Oak Leaf Clusters
Army Achievement Medal
National Defense Service Medal
Iraqi Campaign Medal with Campaign Stars
Global War on Terrorism Service Medal
Army Service Ribbon
Overseas Service Ribbon

PROFESSIONAL AND SOCIETY MEMBERSHIPS

2013-present	Member, South Carolina Rheumatism Soc.
2010-present	Fellow, American College of Physicians
2009-present	Fellow, American College of Rheumatology
2009-present	Member, American Medical Association
2006-present	Member, Georgia Society of Rheumatology
2006-present	Member, Clinical Immunology Society
2001-present	Member, AOA Honor Medical Society

LECTURES/PRESENTATIONS GIVEN AT LOCAL, CHAPTER, NATIONAL, INTERNATIONAL MEETINGS

2010 American College of Rheumatology Annual Scientific Meeting: "Urinary Tract Infection in Rheumatoid Arthritis." Poster Presentation

2010 American College of Physicians Army Chapter Annual Meeting: "Monosodium Urate Crystals in a Rheumatoid Nodule." Poster Presentation

2007 Clinical Immunology Society School for Autoimmune Diseases: "CD4+ T-Lymphocytes Mediate Ischemia/Reperfusion-Induced Inflammatory Responses in Autoimmunity-Prone Mice." Podium Presentation

2006 American College of Rheumatology Annual Scientific Meeting: "The Onset of Autoantibodies Prior to SLE Diagnosis Displays the Complexity of Lupus Humoral Autoimmunity and Suggests Early Roles for Specific Autoantigens." Poster Presentation

2006 American College of Rheumatology Annual Scientific Meeting: "CD4+ T-Lymphocytes Mediate Ischemia/Reperfusion-Induced Inflammatory Responses in Autoimmunity-Prone Mice." Poster presentation

2006 Annual European Congress of Rheumatology (EULAR): "Clinical Criteria of SLE are Present Prior to Diagnosis and are Associated with Specific Autoantibodies." Poster Presentation

2006 Walter Reed Army Medical Center Bailey K Ashford Symposium: "CD4+ T-Lymphocytes Mediate Accelerated Ischemia/Reperfusion-Induced Injury in Autoimmunity-Prone Mice."

2005 Army Chapter ACP: "Symmetric Polyarthritis Following Renal Transplant." Rheumatology Session Presentation

2005 DC Rheumatism Society Intra-city Grand Rounds: "Symmetric Polyarthritis Following Renal Transplant."

2005 District of Columbia Rheumatism Society Fellows' Forum: "Protein Losing Enteropathy in Systemic Lupus Erythematosus." Poster Presentation

2004 Army Chapter ACP: "An Unusual Case of Polyarthritis." Rheumatology Session Presentation

2004 DC Rheumatism Society Intra-city Grand Rounds: "An Unusual Case of Polyarthritis."

2003 Madigan Army Medical Center Research Symposium: "The Effect of Azithromycin on C-Reactive Protein Levels Following Acute Coronary Syndromes, Study Background and Design." Podium Presentation. "Topotecan Induced Lung Injury." Podium Presentation.

2003 Army Chapter ACP: "Rituximab Infusion for the Treatment of Refractory Cryoglobulinemia." Rheumatology Session Presentation

2002 Army Chapter ACP: "Topotecan Induced Lung Injury." Crit. Care Med. Session Presentation

2002 Army Chapter ACP: "Prosthetic Valve Endocarditis Presenting as an ST-Elevation MI." Cardiology Session Poster

2002 Washington State Chapter ACP: "Topotecan Induced Lung Injury." Podium Presentation

BIBLIOGRAPHY

Publications/Journals

Heinlen LD, McClain MT, Ritterhouse LL, Bruner BF, **Edgerton CC**, Keith MP, James JA, Harley JB. 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity. PLoS One. 2010; 5(3): e9599.

Edgerton C, Crispín JC, Moratz CM, Bettelli E, Oukka M, Simovic M, Zacharia A, Egan R, Chen J, Dalle Lucca JJ, Juang YT, Tsokos GC. IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. Clin Immunol. 2009 Mar;130(3):313-21.

Heinlen LD, McClain MT, Merrill J, Akbarali YW, **Edgerton C**, Harley JB, James JA. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. *Arthritis Rheum.* 2007 Jul;56(7):2344-51

Edgerton C, Oglesby RJ. Rheumatoid neutrophilic dermatitis. *Journal of Clinical Rheumatology.* October 2006 12;5: 266-267.

Edgerton C, Oglesby RJ, Straight T. Cryoglobulinemia. *Emedicine.* January 26 2006.

Edgerton C, Roth BJ, Gillman M. Topotecan induced bronchiolitis. *Southern Medical Journal.* July 2004 97;7: 699-701.

Edgerton C, Peterson R. Prosthetic valve endocarditis presenting as an ST-elevation myocardial infarction. *American Family Physician.* February 15 2004 (4): 919-20.

Abstracts

Edgerton C, Michaud K, Wolfe F. Urinary Tract Infections in Rheumatoid Arthritis. (Abstract) *Arthritis Rheum*, 2010;62:S145.

Heinlein L, McClain M, Prestigiacomio T, Bruner B, Binder S, **Edgerton C**, Rubertone M, James J, Harley J. Autoantibody onset prior to SLE diagnosis follows predictable patterns of development. (Abstract). *Clin Immunol.* 2007;123:S101.

Edgerton C, Heinlen L, Roebuck J, Rubertone M, McClain M, Harley J, James J. Clinical criteria for SLE are present prior to diagnosis and are associated with specific autoantibodies. (Abstract). *Ann Rheum Dis* 2006;65(Suppl II):196

Heinlen LD, McClain MT, Bruner BF, **Edgerton C**, Rubertone M, Harley JB, James JA. The onset of autoantibodies prior to SLE diagnosis displays the complexity of lupus humoral autoimmunity and suggests early roles for specific autoantigens. (Abstract) *Arthritis Rheum*, 2006;54(9):1365

Clinical Trials Studies:

1. CORRONA RA Registry. (2013-present); Principal Investigator.
2. The CORRONA effectiveness registry to study therapies for Arthritis and

- inflammatory conditions. (2013-present); Principal Investigator.
3. CORRONA Gout Registry (2013-present); Principal Investigator.
 4. CORRONA PsA and SpA Registry (2013-present); Principal Investigator.
 5. A five-year prospective observational registry to assess AE of interest and effectiveness in adults with active, autoantibody-positive systemic Lupus Erythematosus treated with or without XXXX. (2013 – present); Sub-Investigator
 6. Anti-TNF inhibitor antibody-mediated blockade of drug efficacy in RA. (2013 – present); Sub-investigator
 7. A phase 2b, randomized, double-blind, multicenter, placebo-controlled, parallel-group, dose range finding study JNJ-38518168 in subjects with active Rheumatoid Arthritis despite concomitant Methotrexate therapy. (2014); Sub-Investigator.
 8. A phase 2b, multicenter, open-label study of in RA subjects who completed preceding study M13-390 with XXXX. (2014); Sub-Investigator.
 9. A phase 2, randomized, double-blind assessment of efficacy and safety of PF-04171327 compared to 5mg and 10mg Prednisone daily and placebo daily in subjects with RA over an 8-week period followed by a 4 week period of tapering of study drug. (2014); Sub-Investigator.
 10. A multicenter study of the prevalence of Axial Spondyloarthritis (SpA) in the US among subjects with chronic back pain and other SpA-related features. (2013); Sub-Investigator.
 11. A randomized, double-blind, placebo-controlled phase 3 multicenter study of subcutaneous XXXX in prefilled syringes to demonstrate the efficacy at 16 weeks and to assess the long-term efficacy, safety and tolerability up to 5 years in patients with active Ankylosing Spondylitis. (2013); Sub-Investigator
 12. A phase 3, randomized, double-blind, placebo-controlled, multicenter study of subcutaneous XXXX in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety, tolerability and usability up to 5 years in patient with active RA who have an inadequate response to anti-TNF α agents. (2013-present); Sub-Investigator.
 13. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, pharmacokinetics, and efficacy of VX-509 using MRI and

- Arthroscopic Biopsies in subjects with active RA on stable DMARDs. (2014); Sub-Investigator.
14. A phase 2/3 open-label extension study to evaluate long-term safety and efficacy with VX-509 in a treat-to-target setting in subjects with RA on DMARDs. (2013-present); Sub-Investigator.
 15. A multicenter, randomized, double-blind, saline-controlled study of a single injection of Durolane vs. a single injection of phosphate buffered saline to treat pain associated with OA of the knee. (2013); Sub-Investigator.
 16. A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study of XXXX administered subcutaneously, in subjects with active RA despite anti-TNF α therapy. (2013-present); Sub-Investigator.
 17. A randomized, controlled study of XXXX and MTX versus XXXX and MTX in patients with RA and an inadequate response to 4 months of treatment with XXXX and MTX; (2013 – 2014); Sub-Investigator.
 18. A randomized, double-blind, placebo-controlled, phase 2 study to investigate the safety and efficacy of ABT-494 given with MTX in subjects with moderately to severely active RA who have had an inadequate response or intolerance to Anti-TNF biologic therapy. (2014 – present): Sub-Investigator
 19. A randomized, double-blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with XXXX or XXXX in patients with active Rheumatoid Arthritis previously treated with XXXX. (2015 – 2017); Principal Investigator
 20. A randomized, double-blind, parallel-group Phase III study to demonstrate equivalent efficacy and to compare safety and immunogenicity of GP2015 and XXXX® (EU-authorized) in patients with moderate to severe, active rheumatoid arthritis. (2015 – present); Principal Investigator